肿瘤突变负荷在胃癌中的应用研究进展
作者:
作者单位:

中国人民解放军空军军医大学第一附属医院 胃肠外科,陕西 西安 710032

作者简介:

卫江鹏,中国人民解放军空军军医大学第一附属医院主治医师,主要从事胃肠道肿瘤方面的研究。

通讯作者:

李晓华,Email: xjyylixiaohua@163.com

中图分类号:

R735.2

基金项目:

西京医院助推项目(XJZT19MJ43)。


Research progress in application of tumor mutation burden in gastric cancer
Author:
Affiliation:

Department of Gastrointestinal Surgery, the First Affiliated Hospital of Air Force Medical University, Xi'an 710032, China

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    胃癌属于临床上常见的恶性肿瘤疾病之一,具有高发病率以及高致死率。近年来,免疫检查点抑制剂(ICI)在胃癌的免疫治疗中取得了重大进展。然而整体单药有效率仍较低,也常伴随不同程度的免疫相关不良反应。因此,亟需寻找准确可靠的生物标志物筛选免疫治疗的潜在获益患者。以肿瘤基因变异数目为特征的肿瘤突变负荷(TMB)显示出与ICI疗效的相关性,笔者就TMB与胃癌临床病理关系、免疫治疗效果预测及其他生物标志物关系进行综述。

    Abstract:

    Gastric cancer is one of the most common malignant tumors in clinical practice, and has a high incidence rate and high mortality rate. In recent years, a great progress has been made in the immunotherapy of gastric cancer with immune checkpoint inhibitors (ICIs). However, the overall effective rate of monotherapy is still low, and it is often accompanied by different degrees of immune related adverse reactions. Therefore, it is urgent to find accurate and reliable biomarkers to screen patients with potential benefits from immunotherapy. Tumor mutation burden (TMB), which is characterized by the number of tumor gene mutations, has shown a correlation with the efficacy of ICIs. Here, the authors review the associations of TMB with the clinicopathologic characteristics of gastric cancer, and the prediction of immunotherapy efficacy as well as other biomarkers.

    参考文献
    相似文献
    引证文献
引用本文

卫江鹏,余鹏飞,杨钧,王伟东,高瑞祺,杨西胜,李晓华,季刚.肿瘤突变负荷在胃癌中的应用研究进展[J].中国普通外科杂志,2021,30(10):1229-1234.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2021-04-28
  • 最后修改日期:2021-09-24
  • 录用日期:
  • 在线发布日期: 2021-11-02
  • 出版日期:
新投稿系统运行通知

作者投稿请直接点击左侧“作者登录”,请不要进入旧版入口。如登录或投稿中遇到任何问题,请联系电话18612186403。谢谢!

关闭